Sugi Predict
/ Targets
/ RAD1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to RAD1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer |
PHASE1/PHASE2 | COMPLETED |
| RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects |
PHASE1/PHASE2 | COMPLETED |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations |
PHASE2 | RECRUITING |
| Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer |
PHASE2 | WITHDRAWN |
| Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) |
PHASE1/PHASE2 | UNKNOWN |
| Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer |
PHASE1/PHASE2 | COMPLETED |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck |
PHASE1 | COMPLETED |
| Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer |
PHASE1 | WITHDRAWN |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| Study of the Effect of Innate on the Inflammatory Response to Endotoxin |
nan | RECRUITING |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients |
nan | COMPLETED |
| Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer |
nan | UNKNOWN |
| Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer |
nan | UNKNOWN |
| Prognostic Biomarkers in Patients With Urothelial Carcinoma |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a RAD1 binder may also engage these)